Combination antibody therapy shows promise in metastatic melanoma

(Medical Xpress) -- A duo of drugs, each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase 1 clinical trial led by Dana-Farber Cancer Institute investigators.

The drugs -- ipilimumab and bevacizumab -- are both , intensified formulations of natural disease-fighting proteins. Ipilimumab spurs the immune system to attack diseased cells, including . Bevacizumab, also known by the trade name Avastin, blocks the growth of blood vessels that provide tumors with nourishment. Ipilimumab has extended the lives of metastatic melanoma patients in previous clinical trials, and bevacizumab is often used to treat tumors of the colon, lung, and kidney.

The trial involved 22 patients with metatastic melanoma that was not treatable by surgery.

F. Stephen Hodi, MD, the study's lead author and director of the melanoma treatment center at Dana-Farber, said the trial is the first to explore whether the two agents enhance each other's effectiveness. Most of the participants didn't experience serious adverse side effects, although some did experience inflammation of , the liver, thyroid gland, colon, or uvea (the middle layer of the eye). Five patients required for these problems and were removed the trial.

Positron emission tomography (PET) scans showed a prompt to many of the melanoma tumors, and computed tomography (CT) scans showed decreased blood flow to the tumors. Eight of the participants had partial responses -- showing some -- to the dual treatment, and six had stable disease. All the responses lasted at least six months. Biopsies performed after the treatment showed a more vigorous immune system response than would be expected with ipilimumab alone.

"Our findings indicate that ipilimumab and bevacizumab can be safely administered with careful management of side effects," said Hodi. "The results of lab tests suggest that the two agents may work synergistically, with 14 of 21 evaluable patients experiencing a clinical benefit. This approach merits exploration in further clinical trials."

Provided by Dana-Farber Cancer Institute

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA approves new drug for advanced melanoma

Mar 25, 2011

The U.S. Food and Drug Administration today approved the use of ipilimumab for the treatment of previously treated metastatic melanoma. It is the first drug approved for metastatic, or advanced, melanoma is more than a decade.

New hope for melanoma patients

Jun 07, 2010

(PhysOrg.com) -- A therapy that multiplies the effect of a natural disease-fighting antibody has extended the lives of patients with metastatic melanoma in a large, international clinical trial. The study’s researchers ...

Recommended for you

Is Europe putting cancer research at risk?

2 hours ago

The European Society for Medical Oncology (ESMO), the leading pan-European association representing medical oncology professionals, has expressed concern that the proposed EU General Data Protection Regulation could make ...

Ascertaining low-dose radiation impact on the heart

2 hours ago

We are all exposed to radiations. Such exposure can be harmless at very low doses but damage our health above certain thresholds. But what happens in between is more difficult to predict. The PROCARDIO project is casting ...

User comments